메뉴 건너뛰기




Volumn 51, Issue 1, 2014, Pages 25-34

The Changing Landscape of Peripheral T-Cell Lymphoma in the Era of Novel Therapies

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALISERTIB; BELINOSTAT; BENDAMUSTINE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARMUSTINE; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DENILEUKIN DIFTITOX; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MOGAMULIZUMAB; PANOBINOSTAT; PRALATREXATE; PREDNISONE; ROMIDEPSIN; VINBLASTINE; VINCRISTINE; VINDESINE;

EID: 84892945819     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.11.001     Document Type: Article
Times cited : (28)

References (80)
  • 1
    • 51649091675 scopus 로고    scopus 로고
    • International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes
    • Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
    • (2008) J Clin Oncol , vol.26 , pp. 4124-4130
    • Vose, J.1    Armitage, J.2    Weisenburger, D.3
  • 3
    • 18444404649 scopus 로고    scopus 로고
    • The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas
    • Sonnen R., Schmidt W.P., Muller-Hermelink H.K., Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005, 129:366-372.
    • (2005) Br J Haematol , vol.129 , pp. 366-372
    • Sonnen, R.1    Schmidt, W.P.2    Muller-Hermelink, H.K.3    Schmitz, N.4
  • 4
    • 79953124083 scopus 로고    scopus 로고
    • Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
    • Weisenburger D.D., Savage K.J., Harris N.L., et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011, 117:3402-3408.
    • (2011) Blood , vol.117 , pp. 3402-3408
    • Weisenburger, D.D.1    Savage, K.J.2    Harris, N.L.3
  • 5
    • 84879126115 scopus 로고    scopus 로고
    • Treatment strategies for peripheral T-cell lymphomas
    • Foss F.M. Treatment strategies for peripheral T-cell lymphomas. Best Pract Res Clin Haematol 2013, 26:43-56.
    • (2013) Best Pract Res Clin Haematol , vol.26 , pp. 43-56
    • Foss, F.M.1
  • 6
    • 18044383718 scopus 로고    scopus 로고
    • Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience
    • Escalon M.P., Liu N.S., Yang Y., et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005, 103:2091-2098.
    • (2005) Cancer , vol.103 , pp. 2091-2098
    • Escalon, M.P.1    Liu, N.S.2    Yang, Y.3
  • 7
    • 77956046528 scopus 로고    scopus 로고
    • Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group
    • Gressin R., Caulet-Maugendre S., Deconinck E., et al. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 2010, 95:1350-1357.
    • (2010) Haematologica , vol.95 , pp. 1350-1357
    • Gressin, R.1    Caulet-Maugendre, S.2    Deconinck, E.3
  • 8
    • 0032870340 scopus 로고    scopus 로고
    • CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomised trial
    • Jerkeman M., Anderson H., Cavallin-Stahl E., et al. CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomised trial. Ann Oncol 1999, 10:1079-1086.
    • (1999) Ann Oncol , vol.10 , pp. 1079-1086
    • Jerkeman, M.1    Anderson, H.2    Cavallin-Stahl, E.3
  • 9
    • 78049508777 scopus 로고    scopus 로고
    • Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
    • Schmitz N., Trumper L., Ziepert M., et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010, 116:3418-3425.
    • (2010) Blood , vol.116 , pp. 3418-3425
    • Schmitz, N.1    Trumper, L.2    Ziepert, M.3
  • 10
    • 10744224285 scopus 로고    scopus 로고
    • Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
    • Tilly H., Lepage E., Coiffier B., et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003, 102:4284-4289.
    • (2003) Blood , vol.102 , pp. 4284-4289
    • Tilly, H.1    Lepage, E.2    Coiffier, B.3
  • 11
    • 84869088219 scopus 로고    scopus 로고
    • The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives
    • Yared J., Kimball A. The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat Rev 2013, 39:51-59.
    • (2013) Cancer Treat Rev , vol.39 , pp. 51-59
    • Yared, J.1    Kimball, A.2
  • 12
    • 0037093068 scopus 로고    scopus 로고
    • Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma
    • Gisselbrecht C., Lepage E., Molina T., et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002, 20:2472-2479.
    • (2002) J Clin Oncol , vol.20 , pp. 2472-2479
    • Gisselbrecht, C.1    Lepage, E.2    Molina, T.3
  • 13
    • 0033890745 scopus 로고    scopus 로고
    • Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte Study
    • Haioun C., Lepage E., Gisselbrecht C., et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 2000, 18:3025-3030.
    • (2000) J Clin Oncol , vol.18 , pp. 3025-3030
    • Haioun, C.1    Lepage, E.2    Gisselbrecht, C.3
  • 14
    • 19944425806 scopus 로고    scopus 로고
    • All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
    • Mounier N., Gisselbrecht C., Briere J., et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2004, 15:1790-1797.
    • (2004) Ann Oncol , vol.15 , pp. 1790-1797
    • Mounier, N.1    Gisselbrecht, C.2    Briere, J.3
  • 15
    • 34047159303 scopus 로고    scopus 로고
    • The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience
    • Rodriguez J., Conde E., Gutierrez A., et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007, 18:652-657.
    • (2007) Ann Oncol , vol.18 , pp. 652-657
    • Rodriguez, J.1    Conde, E.2    Gutierrez, A.3
  • 16
    • 34347266576 scopus 로고    scopus 로고
    • Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group
    • Rodriguez J., Conde E., Gutierrez A., et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007, 79:32-38.
    • (2007) Eur J Haematol , vol.79 , pp. 32-38
    • Rodriguez, J.1    Conde, E.2    Gutierrez, A.3
  • 17
    • 58149347800 scopus 로고    scopus 로고
    • Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study
    • Reimer P., Rudiger T., Geissinger E., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009, 27:106-113.
    • (2009) J Clin Oncol , vol.27 , pp. 106-113
    • Reimer, P.1    Rudiger, T.2    Geissinger, E.3
  • 18
    • 43049095718 scopus 로고    scopus 로고
    • Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma
    • Mercadal S., Briones J., Xicoy B., et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008, 19:958-963.
    • (2008) Ann Oncol , vol.19 , pp. 958-963
    • Mercadal, S.1    Briones, J.2    Xicoy, B.3
  • 19
    • 84865712593 scopus 로고    scopus 로고
    • Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
    • d'Amore F., Relander T., Lauritzsen G.F., et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012, 30:3093-3099.
    • (2012) J Clin Oncol , vol.30 , pp. 3093-3099
    • d'Amore, F.1    Relander, T.2    Lauritzsen, G.F.3
  • 20
    • 84892556579 scopus 로고    scopus 로고
    • Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation
    • Gkotzamanidou M., Papadimitriou C.A. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Crit Rev Oncol Hematol 2013, 10.1016/j.critrevonc.2013.08.016.
    • (2013) Crit Rev Oncol Hematol
    • Gkotzamanidou, M.1    Papadimitriou, C.A.2
  • 21
    • 84891076403 scopus 로고    scopus 로고
    • Peripheral T-cell lymphomas: a review of current approaches and hopes for the future
    • Skarbnik A.P., Burki M., Pro B. Peripheral T-cell lymphomas: a review of current approaches and hopes for the future. Front Oncol 2013, 3:138.
    • (2013) Front Oncol , vol.3 , pp. 138
    • Skarbnik, A.P.1    Burki, M.2    Pro, B.3
  • 22
    • 84884727679 scopus 로고    scopus 로고
    • The aggressive peripheral T-cell lymphomas: 2013
    • Armitage J.O. The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol 2013, 88:910-918.
    • (2013) Am J Hematol , vol.88 , pp. 910-918
    • Armitage, J.O.1
  • 23
    • 84885843319 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma
    • Czajczynska A., Gunther A., Repp R., et al. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2013, 19:1632-1637.
    • (2013) Biol Blood Marrow Transplant , vol.19 , pp. 1632-1637
    • Czajczynska, A.1    Gunther, A.2    Repp, R.3
  • 24
    • 84875527567 scopus 로고    scopus 로고
    • Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma
    • Kanakry J.A., Kasamon Y.L., Gocke C.D., et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013, 19:602-606.
    • (2013) Biol Blood Marrow Transplant , vol.19 , pp. 602-606
    • Kanakry, J.A.1    Kasamon, Y.L.2    Gocke, C.D.3
  • 25
    • 84862130917 scopus 로고    scopus 로고
    • Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR
    • e1
    • Hale G.A., Shrestha S., Le-Rademacher J., et al. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant 2012, 18:1036-1043. e1.
    • (2012) Biol Blood Marrow Transplant , vol.18 , pp. 1036-1043
    • Hale, G.A.1    Shrestha, S.2    Le-Rademacher, J.3
  • 26
    • 79952229727 scopus 로고    scopus 로고
    • Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas
    • Reimer P. Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Adv Hematol 2010, 2010:320624.
    • (2010) Adv Hematol , vol.2010 , pp. 320624
    • Reimer, P.1
  • 27
    • 79955029799 scopus 로고    scopus 로고
    • Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)
    • Dearden C.E., Johnson R., Pettengell R., et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011, 153:451-485.
    • (2011) Br J Haematol , vol.153 , pp. 451-485
    • Dearden, C.E.1    Johnson, R.2    Pettengell, R.3
  • 28
    • 47049084821 scopus 로고    scopus 로고
    • ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
    • Savage K.J., Harris N.L., Vose J.M., et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008, 111:5496-5504.
    • (2008) Blood , vol.111 , pp. 5496-5504
    • Savage, K.J.1    Harris, N.L.2    Vose, J.M.3
  • 29
    • 84876966952 scopus 로고    scopus 로고
    • Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
    • Mosse Y.P., Lim M.S., Voss S.D., et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013, 14:472-480.
    • (2013) Lancet Oncol , vol.14 , pp. 472-480
    • Mosse, Y.P.1    Lim, M.S.2    Voss, S.D.3
  • 30
    • 46749135265 scopus 로고    scopus 로고
    • Extranodal NK/T-cell lymphoma: diagnosis and treatment cues
    • Suzuki R., Takeuchi K., Ohshima K., Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol 2008, 26:66-72.
    • (2008) Hematol Oncol , vol.26 , pp. 66-72
    • Suzuki, R.1    Takeuchi, K.2    Ohshima, K.3    Nakamura, S.4
  • 31
    • 84872198307 scopus 로고    scopus 로고
    • Current and future management of NK/T-cell lymphoma based on clinical trials
    • Yamaguchi M. Current and future management of NK/T-cell lymphoma based on clinical trials. Int J Hematol 2012, 96:562-571.
    • (2012) Int J Hematol , vol.96 , pp. 562-571
    • Yamaguchi, M.1
  • 32
    • 33644835980 scopus 로고    scopus 로고
    • Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma
    • Li Y.X., Yao B., Jin J., et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006, 24:181-189.
    • (2006) J Clin Oncol , vol.24 , pp. 181-189
    • Li, Y.X.1    Yao, B.2    Jin, J.3
  • 33
    • 84869456017 scopus 로고    scopus 로고
    • Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211
    • Yamaguchi M., Tobinai K., Oguchi M., et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol 2012, 30:4044-4046.
    • (2012) J Clin Oncol , vol.30 , pp. 4044-4046
    • Yamaguchi, M.1    Tobinai, K.2    Oguchi, M.3
  • 34
    • 34250659715 scopus 로고    scopus 로고
    • CMED in the treatment of nasal natural killer cell lymphoma with distant metastases
    • Aviles A., Cleto S., Castaneda C., Nambo M.J. CMED in the treatment of nasal natural killer cell lymphoma with distant metastases. Hematology 2007, 12:241-244.
    • (2007) Hematology , vol.12 , pp. 241-244
    • Aviles, A.1    Cleto, S.2    Castaneda, C.3    Nambo, M.J.4
  • 35
    • 43649085643 scopus 로고    scopus 로고
    • Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia
    • Yamaguchi M., Suzuki R., Kwong Y.L., et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008, 99:1016-1020.
    • (2008) Cancer Sci , vol.99 , pp. 1016-1020
    • Yamaguchi, M.1    Suzuki, R.2    Kwong, Y.L.3
  • 36
    • 84867810745 scopus 로고    scopus 로고
    • SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group
    • Kwong Y.L., Kim W.S., Lim S.T., et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012, 120:2973-2980.
    • (2012) Blood , vol.120 , pp. 2973-2980
    • Kwong, Y.L.1    Kim, W.S.2    Lim, S.T.3
  • 37
    • 81755172136 scopus 로고    scopus 로고
    • Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study
    • Yamaguchi M., Kwong Y.L., Kim W.S., et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011, 29:4410-4416.
    • (2011) J Clin Oncol , vol.29 , pp. 4410-4416
    • Yamaguchi, M.1    Kwong, Y.L.2    Kim, W.S.3
  • 38
    • 79951483189 scopus 로고    scopus 로고
    • Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study
    • Jaccard A., Gachard N., Marin B., et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011, 117:1834-1839.
    • (2011) Blood , vol.117 , pp. 1834-1839
    • Jaccard, A.1    Gachard, N.2    Marin, B.3
  • 39
    • 33645210475 scopus 로고    scopus 로고
    • Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors
    • Yong W., Zheng W., Zhu J., et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol 2006, 24:28-32.
    • (2006) Hematol Oncol , vol.24 , pp. 28-32
    • Yong, W.1    Zheng, W.2    Zhu, J.3
  • 41
    • 84858653535 scopus 로고    scopus 로고
    • How I treat enteropathy-associated T-cell lymphoma
    • Di Sabatino A., Biagi F., Gobbi P.G., Corazza G.R. How I treat enteropathy-associated T-cell lymphoma. Blood 2012, 119:2458-2468.
    • (2012) Blood , vol.119 , pp. 2458-2468
    • Di Sabatino, A.1    Biagi, F.2    Gobbi, P.G.3    Corazza, G.R.4
  • 42
    • 77952578954 scopus 로고    scopus 로고
    • Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation
    • Sieniawski M., Angamuthu N., Boyd K., et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010, 115:3664-3670.
    • (2010) Blood , vol.115 , pp. 3664-3670
    • Sieniawski, M.1    Angamuthu, N.2    Boyd, K.3
  • 43
    • 33847339853 scopus 로고    scopus 로고
    • Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells
    • Al-toma A., Visser O.J., van Roessel H.M., et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007, 109:2243-2249.
    • (2007) Blood , vol.109 , pp. 2243-2249
    • Al-toma, A.1    Visser, O.J.2    van Roessel, H.M.3
  • 44
    • 34948824913 scopus 로고    scopus 로고
    • Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
    • Gallamini A., Zaja F., Patti C., et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007, 110:2316-2323.
    • (2007) Blood , vol.110 , pp. 2316-2323
    • Gallamini, A.1    Zaja, F.2    Patti, C.3
  • 45
    • 84993707686 scopus 로고    scopus 로고
    • Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    • Marchi E, O'Connor OA. Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Ther Adv Hematol;3:227-35.
    • Ther Adv Hematol , vol.3 , pp. 227-35
    • Marchi, E.1    O'Connor, O.A.2
  • 47
    • 0037409795 scopus 로고    scopus 로고
    • Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression
    • Wang E.S., O'Connor O., She Y., Zelenetz A.D., Sirotnak F.M., Moore M.A. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003, 44:1027-1035.
    • (2003) Leuk Lymphoma , vol.44 , pp. 1027-1035
    • Wang, E.S.1    O'Connor, O.2    She, Y.3    Zelenetz, A.D.4    Sirotnak, F.M.5    Moore, M.A.6
  • 48
    • 32944480860 scopus 로고    scopus 로고
    • The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma
    • Toner L.E., Vrhovac R., Smith E.A., et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006, 12:924-932.
    • (2006) Clin Cancer Res , vol.12 , pp. 924-932
    • Toner, L.E.1    Vrhovac, R.2    Smith, E.A.3
  • 49
    • 77954755959 scopus 로고    scopus 로고
    • Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies
    • Marchi E., Paoluzzi L., Scotto L., et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 2010, 16:3648-3658.
    • (2010) Clin Cancer Res , vol.16 , pp. 3648-3658
    • Marchi, E.1    Paoluzzi, L.2    Scotto, L.3
  • 50
    • 70349310325 scopus 로고    scopus 로고
    • Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
    • O'Connor O.A., Horwitz S., Hamlin P., et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009, 27:4357-4364.
    • (2009) J Clin Oncol , vol.27 , pp. 4357-4364
    • O'Connor, O.A.1    Horwitz, S.2    Hamlin, P.3
  • 51
    • 79952749741 scopus 로고    scopus 로고
    • Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
    • O'Connor O.A., Pro B., Pinter-Brown L., et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011, 29:1182-1189.
    • (2011) J Clin Oncol , vol.29 , pp. 1182-1189
    • O'Connor, O.A.1    Pro, B.2    Pinter-Brown, L.3
  • 52
    • 84871758096 scopus 로고    scopus 로고
    • Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial
    • Damaj G., Gressin R., Bouabdallah K., et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013, 31:104-110.
    • (2013) J Clin Oncol , vol.31 , pp. 104-110
    • Damaj, G.1    Gressin, R.2    Bouabdallah, K.3
  • 53
    • 84881090160 scopus 로고    scopus 로고
    • Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma
    • Hassler M.R., Schiefer A.I., Egger G. Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma. Epigenomics 2013, 5:397-415.
    • (2013) Epigenomics , vol.5 , pp. 397-415
    • Hassler, M.R.1    Schiefer, A.I.2    Egger, G.3
  • 54
    • 2942535832 scopus 로고    scopus 로고
    • T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
    • Piekarz R.L., Robey R.W., Zhan Z., et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004, 103:4636-4643.
    • (2004) Blood , vol.103 , pp. 4636-4643
    • Piekarz, R.L.1    Robey, R.W.2    Zhan, Z.3
  • 55
    • 79952977561 scopus 로고    scopus 로고
    • Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
    • Piekarz R.L., Frye R., Prince H.M., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117:5827-5834.
    • (2011) Blood , vol.117 , pp. 5827-5834
    • Piekarz, R.L.1    Frye, R.2    Prince, H.M.3
  • 57
    • 84892910948 scopus 로고    scopus 로고
    • A phase Ib/II trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the Ro-CHOP study
    • [abstract 18]
    • Dupuis J., Morschhauser F., Ghesquieres H., et al. A phase Ib/II trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the Ro-CHOP study. Hematol Oncol 2013, 31(Suppl 1):135. [abstract 18].
    • (2013) Hematol Oncol , vol.31 , Issue.SUPPL. 1 , pp. 135
    • Dupuis, J.1    Morschhauser, F.2    Ghesquieres, H.3
  • 58
    • 84884558230 scopus 로고    scopus 로고
    • Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial
    • [abstract 8507]
    • O'Connor O., Masszi T., Savage K., et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial. J Clin Oncol 2013, 31(Suppl). [abstract 8507].
    • (2013) J Clin Oncol , vol.31 , Issue.SUPPL.
    • O'Connor, O.1    Masszi, T.2    Savage, K.3
  • 59
    • 84872107995 scopus 로고    scopus 로고
    • Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial
    • Duvic M., Dummer R., Becker J.C., et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 2013, 49:386-394.
    • (2013) Eur J Cancer , vol.49 , pp. 386-394
    • Duvic, M.1    Dummer, R.2    Becker, J.C.3
  • 61
    • 84859984909 scopus 로고    scopus 로고
    • Overview of alemtuzumab therapy for the treatment of T-cell lymphomas
    • Zinzani P.L., Corradini P., Gallamini A., et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma 2012, 53:789-795.
    • (2012) Leuk Lymphoma , vol.53 , pp. 789-795
    • Zinzani, P.L.1    Corradini, P.2    Gallamini, A.3
  • 62
    • 1842579580 scopus 로고    scopus 로고
    • A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
    • Enblad G., Hagberg H., Erlanson M., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103:2920-2924.
    • (2004) Blood , vol.103 , pp. 2920-2924
    • Enblad, G.1    Hagberg, H.2    Erlanson, M.3
  • 63
    • 34247397835 scopus 로고    scopus 로고
    • Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study
    • Kim J.G., Sohn S.K., Chae Y.S., et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007, 60:129-134.
    • (2007) Cancer Chemother Pharmacol , vol.60 , pp. 129-134
    • Kim, J.G.1    Sohn, S.K.2    Chae, Y.S.3
  • 65
    • 10744222473 scopus 로고    scopus 로고
    • Development of potent monoclonal antibody auristatin conjugates for cancer therapy
    • Doronina S.O., Toki B.E., Torgov M.Y., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003, 21:778-784.
    • (2003) Nat Biotechnol , vol.21 , pp. 778-784
    • Doronina, S.O.1    Toki, B.E.2    Torgov, M.Y.3
  • 66
    • 78049515807 scopus 로고    scopus 로고
    • Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
    • Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
    • (2010) N Engl J Med , vol.363 , pp. 1812-1821
    • Younes, A.1    Bartlett, N.L.2    Leonard, J.P.3
  • 67
    • 84863678237 scopus 로고    scopus 로고
    • Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
    • Pro B., Advani R., Brice P., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012, 30:2190-2196.
    • (2012) J Clin Oncol , vol.30 , pp. 2190-2196
    • Pro, B.1    Advani, R.2    Brice, P.3
  • 69
    • 77951916883 scopus 로고    scopus 로고
    • Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma
    • Yamamoto K., Utsunomiya A., Tobinai K., et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010, 28:1591-1598.
    • (2010) J Clin Oncol , vol.28 , pp. 1591-1598
    • Yamamoto, K.1    Utsunomiya, A.2    Tobinai, K.3
  • 70
    • 84863393084 scopus 로고    scopus 로고
    • Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study
    • Ishida T., Joh T., Uike N., et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012, 30:837-842.
    • (2012) J Clin Oncol , vol.30 , pp. 837-842
    • Ishida, T.1    Joh, T.2    Uike, N.3
  • 71
    • 84892927850 scopus 로고    scopus 로고
    • The efficacy and safety of mogamulizumab (KW-0761) in multicentre phase II study for patients with relapsed peripheral or cutaneous T-cell lymphoma
    • [abstract 41]
    • Ueda R., Ogura M., Ishida T., et al. The efficacy and safety of mogamulizumab (KW-0761) in multicentre phase II study for patients with relapsed peripheral or cutaneous T-cell lymphoma. Hematol Oncol 2013, 31(Suppl 1):109. [abstract 41].
    • (2013) Hematol Oncol , vol.31 , Issue.SUPPL. 1 , pp. 109
    • Ueda, R.1    Ogura, M.2    Ishida, T.3
  • 72
    • 84876414545 scopus 로고    scopus 로고
    • Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma
    • Ishida T., Ito A., Sato F., et al. Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 2013, 104:647-650.
    • (2013) Cancer Sci , vol.104 , pp. 647-650
    • Ishida, T.1    Ito, A.2    Sato, F.3
  • 73
    • 77953347770 scopus 로고    scopus 로고
    • Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
    • Kaminetzky D., Hymes K.B. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics 2008, 2:717-724.
    • (2008) Biologics , vol.2 , pp. 717-724
    • Kaminetzky, D.1    Hymes, K.B.2
  • 74
    • 33846010137 scopus 로고    scopus 로고
    • Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
    • Dang N.H., Pro B., Hagemeister F.B., et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136:439-447.
    • (2007) Br J Haematol , vol.136 , pp. 439-447
    • Dang, N.H.1    Pro, B.2    Hagemeister, F.B.3
  • 75
    • 79952263752 scopus 로고    scopus 로고
    • Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial
    • [abstract 8045]
    • Foss F., Sjak-Shie N., Goy A., Advani R., Jacobsen E. Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. J Clin Oncol 2010, Suppl:15s:28. [abstract 8045].
    • (2010) J Clin Oncol , vol.15 S , pp. 28
    • Foss, F.1    Sjak-Shie, N.2    Goy, A.3    Advani, R.4    Jacobsen, E.5
  • 76
    • 77957566161 scopus 로고    scopus 로고
    • Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma
    • Dueck G., Chua N., Prasad A., et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010, 116:4541-4548.
    • (2010) Cancer , vol.116 , pp. 4541-4548
    • Dueck, G.1    Chua, N.2    Prasad, A.3
  • 77
    • 84881109532 scopus 로고    scopus 로고
    • A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial
    • Morschhauser F., Fitoussi O., Haioun C., et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 2013, 49:2869-2876.
    • (2013) Eur J Cancer , vol.49 , pp. 2869-2876
    • Morschhauser, F.1    Fitoussi, O.2    Haioun, C.3
  • 78
    • 84892916318 scopus 로고    scopus 로고
    • Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas
    • Friedberg J.W., Mahadevan D., Cebula E., et al. Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014, 32:44-50.
    • (2014) J Clin Oncol , vol.32 , pp. 44-50
    • Friedberg, J.W.1    Mahadevan, D.2    Cebula, E.3
  • 79
    • 84872456641 scopus 로고    scopus 로고
    • Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral T-Cell Lymphoma Project
    • Federico M., Rudiger T., Bellei M., et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral T-Cell Lymphoma Project. J Clin Oncol 2013, 31:240-246.
    • (2013) J Clin Oncol , vol.31 , pp. 240-246
    • Federico, M.1    Rudiger, T.2    Bellei, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.